Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Sitagliptin Monotherapy in Japanese T2D
NCT02254291Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02254291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02254291.